Am Fam Physician. 1990 Feb;41(2):589-91.

Selegiline for Parkinson's disease.

Source

Hahnemann University School of Medicine, Philadelphia, Pennsylvania.

Abstract

Monoamine oxidase inhibitors that have been available in the United States are nonselective and thus act equally on peripheral and brain monoamine oxidase. Recently, selegiline, a selective monoamine oxidase inhibitor, has been approved for use in the management of Parkinson's disease. Clinical trials demonstrate that selegiline in combination with carbidopa/levodopa is effective in relieving symptoms and prolonging remission. The dosage of carbidopa/levodopa can usually be reduced, resulting in diminished side effects. Selegiline is relatively nontoxic and appears to be a valuable addition in the management of Parkinson's disease.

PMID:: 2105624; [PubMed - indexed for MEDLINE]

Publication Types, MeSH Terms, Substances

Publication Types

Clinical Trial

MeSH Terms

Substances

LinkOut - more resources

Medical

Parkinson's Disease - MedlinePlus Health Information

Supplemental Content

Save items

Related citations in PubMed

Review Recent advances in Parkinson's disease therapy: use of monoamine oxidase inhibitors. [Expert Rev Neurother. 2005]
Review Recent advances in Parkinson's disease therapy: use of monoamine oxidase inhibitors.
Henchcliffe C, Schumacher HC, Burgut FT. Expert Rev Neurother. 2005 Nov; 5(6):811-21.
Selegiline: a second look. Six years later: too risky in Parkinson's disease. [Prescrire Int. 2002]
Selegiline: a second look. Six years later: too risky in Parkinson's disease.
. Prescrire Int. 2002 Aug; 11(60):108-11.
Selegiline in Parkinson's disease. [BMJ. 1995]
Selegiline in Parkinson's disease.
Calne DB. BMJ. 1995 Dec 16; 311(7020):1583-4.
Review [Biochemical basis for using selective monoamine oxidase inhibitors in the treatment of Parkinson's disease. Critical contribution]. [Riv Neurol. 1985]
Review [Biochemical basis for using selective monoamine oxidase inhibitors in the treatment of Parkinson's disease. Critical contribution].
Amato L, Nava L, Rizzo M, Piccoli F. Riv Neurol. 1985 Jan-Feb; 55(1):46-52.
Review Safety of selegiline (deprenyl) in the treatment of Parkinson's disease. [Drug Saf. 1998]
Review Safety of selegiline (deprenyl) in the treatment of Parkinson's disease.
Heinonen EH, Myllylä V. Drug Saf. 1998 Jul; 19(1):11-22.

See reviews... See all...

Related information

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
Compound (MeSH Keyword)
PubChem chemical compound records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Substance (MeSH Keyword)
PubChem chemical substance (submitted) records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.

Recent activity

Clear Turn Off Turn On

Selegiline for Parkinson's disease.
Selegiline for Parkinson's disease.
Am Fam Physician. 1990 Feb ;41(2):589-91.

PubMed
Molecular neurobiology of circadian rhythms.
Molecular neurobiology of circadian rhythms.
Handb Clin Neurol. 2011 ;99:951-61.

PubMed
Intracranial ependymoma and subependymoma: MR manifestations.
Intracranial ependymoma and subependymoma: MR manifestations.
AJNR Am J Neuroradiol. 1990 Jan-Feb ;11(1):83-91.

PubMed
Strength and endurance of the pelvic floor muscles in continent women: an observ...
Strength and endurance of the pelvic floor muscles in continent women: an observational study.
Physiotherapy. 2010 Dec ;96(4):311-6. Epub 2010 May 6 .

PubMed
The cerebellum: 3. Anatomic-MR correlation in the coronal plane.
The cerebellum: 3. Anatomic-MR correlation in the coronal plane.
AJNR Am J Neuroradiol. 1990 Jan-Feb ;11(1):41-50.

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Result Filters

Display Settings:

Send to: